CSI and InformDx are each a division of Fulgent Genetics. Xie will remain responsible for managing Fulgent’s global operations, product vision and product engineering.Ĭhris Wicker has been appointed as Vice President and General Manager of CSI Laboratories (“CSI”) and Inform Diagnostics (“InformDx”). Xie has been a key member of Fulgent’s executive team since the Company’s founding and has made meaningful contributions to the business through his leadership and commitment to Fulgent’s growth and expansion. James Xie, Fulgent’s Chief Operating Officer, has been named President in addition to his current role. As an organization, we pride ourselves on disciplined execution, cohesiveness and commitment to excellence, and I am pleased that each of these individuals helps to fulfill the values of Fulgent Genetics through their leadership.” “We are pleased to announce a number of promotions and leadership updates across the business as we continue to execute on our strategy of rapid growth and expansion. “The deep domain expertise and leadership experience of our senior team has been instrumental in driving our success in recent years,” said Ming Hsieh, Chairman and CEO of Fulgent Genetics. (NASDAQ: FLGT) (“Fulgent Genetics”, “Fulgent”, or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced a number of promotions and appointments across its leadership team. TEMPLE CITY, Calif.-(BUSINESS WIRE)-May 3, 2022-įulgent Genetics, Inc.
0 kommentar(er)
